Why the study?
The Japanese Circulation Society recently published new guidelines for the diagnosis and treatment of cardiac sarcoidosis, prompting a comparison of management aspects with the Heart Rhythm Society guidelines.
This document provides a comparative overview of the HRS and JCS guidelines for the management of cardiac sarcoidosis.
Answers are grounded in this paper and cite their sources.
Highlights differing HRS/JCS recommendations on immunosuppression and devices in cardiac sarcoidosis; leaves optimal strategies open for prospective trials.
Introduction: The Japanese Circulation Society (JCS) recently published new guidelines for the diagnosis and treatment of Cardiac Sarcoidosis (CS). There are two other guideline documents, the World Association of Sarcoidosis and Other Granulomatous Disorders Sarcoidosis Organ (WASOG) Assessment Instrument created in 1999 and updated in 2014. Also, in 2014, the Heart Rhythm Society (HRS) published their international guideline document. As co-chair of the HRS document I have been invited to compare and contrast the management aspects of the HRS guidelines with the new JCS document.
No takes yet. Share an insight, caveat, or question.
Birnie et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: